Simultaneous study of the metabolic turnover and renal excretion of salivary amylase- 125 I and pancreatic amylase- 131 I in the baboon.

The metabolic turnover of salivary and pancreatic amylase was studied in the baboon, an animal with a serum amylase level and renal clearance of amylase similar to man. Purified amylase was electrolytically iodinated. Although iodinated and uniodinated amylase had similar gel filtration, electrophoretic, enzymatic, glycogen precipitation characteristics, the labeled enzyme was cleared less rapidly by the kidney than was the unlabeled material. However, urinary iodinated amylase which had been biologically screened by the kidney had a renal clearance and serum disappearance rate indistinguishable from unlabeled amylase and thus can serve as a tracer in metabolic turnover studies. Administration of a mixture of salivary amylase-(125)I and pancreatic amylase-(131)I made it possible to simultaneously measure the serum disappearance and renal clearance of these two isoenzymes. The metabolic clearance of both isoenzymes was extremely rapid with half-times of about 130 min. This rapid turnover of serum amylase probably accounts for the transient nature of serum amylase elevation which frequently occurs in pancreatitis. Pancreatic amylase-(131)I was consistently cleared more rapidly (mean clearance ratio: 1.8) by the kidney than was salivary amylase-(125)I. This more rapid renal clearance of pancreatic amylase may help to explain the disproportionate elevation of urinary amylase relative to serum amylase observed in pancreatitis.

Saliva-based HIV-antibody testing in Thailand.

OBJECTIVE: To determine whether saliva could serve as an alternative to serum for HIV-antibody testing in an ongoing sentinel surveillance program in Thailand. METHODS: Serum and saliva specimens were collected from 1955 individuals in four of the 73 sentinel sites of the national surveillance program in Thailand. Intravenous drug users, female prostitutes, and men attending sexually transmitted disease clinics were included as participants. All specimens were collected and tested anonymously. Saliva was gathered with the Omni-Sal collection device and analyzed for the presence of HIV antibodies using the immunoglobulin G antibody-capture enzyme-linked immunosorbent assay (GACELISA) laboratory test, specially designed for low concentration body fluids. Our gold standard was serum, collected and analyzed independently from the saliva specimens, using an ELISA test for screening and Western blot for confirmation. Linkage between serum and saliva was blind to the laboratory. A set of HIV-positive and HIV-negative quality assurance samples for both serum and saliva were also analyzed blind. RESULTS: Findings are presented as observed in the field, and as quality assurance samples after the correction of various field and laboratory errors. The sensitivity of the GACELISA with saliva was 98.0% in the field (298 HIV-positive specimens), 100% after correction of errors (300 HIV-positive specimens), and 100% among the quality assurance samples (95 HIV-positive specimens). The specificity of the GACELISA was 99.4% in the field (1653 HIV-negative specimens), 99.6% after correction of errors (1654 HIV-negative specimens), and 100% among the quality assurance samples (96 HIV-negative specimens). CONCLUSION: Our findings support other published studies that also featured the GACELISA. We conclude that saliva is comparable to serum for assessing HIV antibodies in individuals for surveillance and screening purposes.

Comparison of saliva and serum for HIV surveillance in developing countries.

Saliva has been proposed as a non-invasive alternative to serum for HIV antibody testing. In a field study in Myanmar (formerly Burma), we evaluated such an alternative to identify the frequency of HIV infection in a surveillance programme of high-risk and low-risk sentinel groups. Duplicate vials of saliva and serum were collected from 479 high-risk and 1039 low-risk subjects. One vial of each pair was analysed blind in two laboratories, one in the USA and the other in Myanmar. The US laboratory followed WHO confirmatory strategy III with three different enzyme-linked immunosorbent assays (ELISAs), while the laboratory in Myanmar followed strategy I with one ELISA. Serum testing in the US was the gold standard. The Cambridge ELISA with saliva was a more effective surveillance tool (sensitivity 90.5%, specificity 99.5-100%) for describing the frequency of subjects with HIV antibodies than the serum ELISA supplied to Myanmar by WHO (95.9% and 98.3%, respectively). Saliva is recommended as a safe and effective alternative to serum for HIV antibody testing with ELISA in surveillance programmes in developing countries.

PIP: HIV infection is becoming increasingly prevalent in Myanmar. More widespread HIV testing is therefore needed to make people aware that HIV has reached their community and convince them that preventive measures must be taken. The expense of blood serum testing, however, generally makes such widespread testing nonviable for developing countries. Testing saliva for the presence of antibodies to HIV has been suggested as a noninvasive alternative to testing serum. In testing saliva, needlestick injuries would be avoided, highly trained personnel would not be needed, many subjects could be sampled simultaneously, subjects might prefer to give saliva samples instead of blood, and costs would be lower. 479 high-risk and 1039 low-risk subjects were recruited for the study from Myanmar. Their saliva and serum samples were then tested in both the US and Myanmar. 3 ELISA tests were used to test serum in the US in keeping with World Health Organization confirmatory strategy III. Only one ELISA was performed in the Myanmar laboratory. The Cambridge ELISA proved most effective in identifying the number of subjects with HIV antibodies. The authors recommend testing saliva instead of serum for HIV surveillance programs in developing countries. Given the Cambridge ELISA 10% false-negative rate in the Myanmar laboratory and the 5% false-negative rate in the US laboratory, saliva testing is, however, inadequate for diagnostic testing and should be used exclusively for surveillance purposes.

Stability of saliva for measuring HIV in the tropics.

If HIV is to be detected among pregnant women in remote regions of the tropics, HIV antibodies need to remain stable until specimens arrive at the laboratory. Our objective was to assess the stability of HIV antibodies in saliva held for up to 1 month at ambient temperature in Yangon, Myanmar. We gathered 10 saliva specimens from each of 102 HIV-infected persons with the Omni-Sal collection device (Saliva Diagnostic Systems, Inc.), and for each subject, divided the saliva into 15 portions. During 33 days, the 102 saliva specimens, kept at ambient temperature, were tested every 2-3 days for HIV antibodies (total 1530 assays) with the GACELISA (Murex Diagnostics Ltd), a highly sensitive test designed for use with saliva. We observed no reduction in test performance over 33 days, indicating that the antimicrobial and antiproteolytic transport medium in the Omni-Sal device can preserve HIV antibodies without refrigeration for up to a month before saliva specimens reach the laboratory.